Metsera raises $215m in Series B round for weight loss candidates
Despite the competitive nature for funding in the crowded weight loss treatment space, Metsera has won $215m to advance its…
Metabolic Disorders
-
-
Intercept loses Ocaliva FDA full approval bid in rare liver disease
On the heels of an unfavourable advisory committee (AdCom) meeting, the US Food and Drug Administration (FDA) has decided not…
-
Ultra-processed food is causing a boom for obesity drug Ozempic
The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs. One example…
-
Strong Wegovy revenue growth for Novo Nordisk but shares dip
Novo Nordisk has reported net Q3 profits of $3.94bn (DKr27.3bn) fuelled by better-than-expected sales for its blockbuster weight loss drug…
-
NLS and Kadimastem stocks soar following merger agreement
Switzerland-based NLS Pharmaceutics and Israel-headquartered Kadimastem have signed a definitive merger agreement, with plans to form a joint biopharmaceutical aimed…
-
Lexicon stock tumbles after FDA AdCom votes against Zynquista again
The US Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (AdCom) has again voted against the approval…
-
Pharmacists claim “desperation” by Novo Nordisk over semaglutide copycat block
In the same week that Eli Lilly filed three lawsuits against online vendors and wellness spas making compounded versions of…
-
MangoRx hits back at Eli Lilly’s weight loss drug copycat claims
MangoRx said it “strongly refutes” claims made by Eli Lilly that it improperly copied blockbuster weight-loss medicines for sale on…
-
Novo Nordisk plans label expansion for Rybelsus following Phase III win
Novo Nordisk plans to file a label expansion for Rybelsus (oral semaglutide) as an adjunct treatment for the prevention of…
-
TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan Africa for T2D
TheracosBio has entered a partnership with BAMCO Africa to deliver BRENZAVVY (bexagliflozin), a type 2 diabetes (T2D) treatment, to patients…
